<DOC>
	<DOC>NCT01843972</DOC>
	<brief_summary>To investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of single rising doses of BI 691751 in healthy male subjects (part I). To investigate the relative bioavailability of BI 691751 given as tablet versus oral solution (part II)</brief_summary>
	<brief_title>Safety of Single Rising Doses and Relative Bioavailability of BI 691751</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion criteria: 1. Healthy male subjects 2. Subjects must be able to understand and comply with study requirements 3. Age from 18 to 55 years 4. BMI range: from 18.5 to 29.9 kg/m2 5. Known genotype as specified in the study protocol Exclusion criteria: 1. Any relevant deviation from healthy conditions</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>